VRUS – dewophile, genisi et al: We’ll no longer be able to evaluate VRUS’ (probably bogus) claims that Clevudine was uniquely able to generate SVR’s. I never bought the company’s grandiose assertions about Clevudine’s MoA (#msg-36818344, #msg-36818563), but it would’ve been nice to know one way or the other.
VRUS is down only 11% today; investors evidently hadn’t ascribed much value to Clevudine relative to VRUS’ programs in HCV.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.